Medi-Maa (Macrosalb (99mtc))

Macrosalb is labeled with technetium‑99m, which emits gamma radiation. After intravenous injection, the compound binds to specific cellular targets, and the emitted photons are detected by a gamma camera, creating detailed images that reflect the physiological state of the targeted tissue.

The dose of Medi-Maa is determined by the prescribing physician based on the specific imaging protocol, patient weight, and the organ system being examined. Dosing is individualized and should follow the radiopharmacy’s preparation guidelines.

Medi-Maa should only be used during pregnancy or breastfeeding when the diagnostic benefit clearly outweighs the potential radiation risk to the fetus or infant. Physicians must evaluate each case and discuss possible risks with the patient.

To order Medi-Maa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Medi-Maa, containing Macrosalb labeled with technetium‑99m, offers high‑resolution gamma emission suitable for a range of imaging studies. Compared with PET tracers, it provides longer half‑life and easier logistics, while delivering comparable diagnostic information for many clinical indications.

Medi-Maa must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. It should be kept in its original container until use, and handling must follow radiation safety guidelines to protect personnel.

Medi-Maa is administered intravenously by a qualified healthcare professional. The injection is typically performed in a controlled environment, and imaging is conducted shortly after administration according to the specific protocol for the organ of interest.

The most serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, and radiation‑related tissue injury. Patients should be monitored closely during and after administration, and emergency measures should be readily available.

Medi-Maa is contraindicated in patients with known hypersensitivity to technetium‑99m or any excipients in the formulation, and it should be avoided in pregnant women unless absolutely necessary. Patients with severe renal impairment may also be unsuitable without specialist assessment.